Skip to main content

Table 3 Basic description of the participating women

From: Health services research in patients with breast cancer (CAMISS-prospective): study protocol for an observational prospective study

 

Total N = 1456

 

Surgery

No surgery

 

1432 (98.35%)

24 (1.65%)

Age, yearsa

57.604 (11.917)

80.575 (11.257)

Charlson comorbidity indexa

0.325 (0.752)

0.958 (1.197)

Initial treatment

  

Conservative

648 (45.25%)

–

Simple mastectomy

203 (14.18%)

–

Radical mastectomy

38 (2.65%)

–

Radical modified mastectomy

46 (3.21%)

–

Neoadjuvant therapy

165 (11.52%)

22 (91.67%)

Adjuvant therapy

  

Chemotherapy1

455 (31.77%)

 

ACT

166 (11.59%)

 

TAC

80 (5.59%)

 

CMF

8 (0.56%)

 

FEC

42 (2.93%)

 

FEC-Taxane

41 (2.86%)

 

TC

35 (2.44%)

 

Other

88 (6.15%)

 

Radiotherapy (yes)

1126 (78.63%)

 

Hormone therapy

1146 (80.03%)

 

Tamoxifen

484 (33.8%)

 

Tamoxifen +GnRH analogues2

50 (3.49%)

 

Tamoxifen +Aromatase inhibitors

12 (0.84%)

 

Aromatase inhibitors

639 (44.62%)

 

Others

26 (1.82%)

 

TNM3

  

0

135 (9.43%)

0

I

683 (47.7%)

2 (8.33%)

II

453 (31.63%)

5 (20.83%)

III

134 (9.36%)

4 (16.67%)

IV

18 (1.26%)

11 (45.83%)

  1. 1.-Chemotherapy:
  2. ACT Adriamycin/ doxorrubicine, cyclophosphamide + taxane (docetaxel / paclitaxel),
  3. TAC docetaxel, Adriamycin, cyclophosphamide,
  4. CMF cyclophosphamide, Methotrexate 5-Fluorouracil
  5. FAC 5-fluorouracil, Adriamycin (Doxorubicin), cyclophosphamide- FEC: 5-fluorouracil, epirubicin, cyclophosphamide
  6. FEC-Taxane FEC + paclitaxel
  7. TC Taxane, cyclophosphamide
  8. 2.- GnRH Gonadotropin-releasing hormone analogues
  9. 3.-pTNM pathological tumor-node-metastasis staging in patients who underwent surgery
  10. aMeans and, in brackets, standard deviation